SkinlogieEvidence before expense.
ENFRESDEPT
Find your guide

Trust + expectations

Who pays for skin research, and what that changes

Industry funds roughly two thirds of acne, eczema and psoriasis trials — and only a quarter of melasma trials. The pattern shapes which treatments exist.

By Patrick and Michelle8 min read
Article in one pictureWho pays decides what gets asked
  • Industry funds most65 to 69 percent across three conditions
  • Melasma: 24 percentCheap off-patent treatments attract no sponsor
  • Check the comparatorBeating a placebo is a low bar
Roughly two thirds of acne, eczema and psoriasis trials are company-funded. Melasma is not.
On this pageThe split, condition by condition5

Quick answer

The bottom line

Companies fund most skin research: 65 percent of acne trials, 69 percent of eczema trials and 67 percent of psoriasis trials in our snapshot. Melasma is the outlier at 24 percent, and it shows — 131 studies have produced only 4 with posted results. Use this when a treatment seems oddly under-researched: often the gap reflects who stood to profit rather than what patients needed. Industry funding is not a reason to dismiss a result, because those trials are usually the largest and best controlled, but it does predict which questions never get asked.

At a glance

Three things worth remembering

  1. Industry sponsors 410 of 629 acne trials, 869 of 1,255 eczema trials and 1,057 of 1,576 psoriasis trials in our snapshot.[1][2]
  2. Melasma reverses the pattern: 31 of 131 trials are industry-funded, and only 4 completed studies have posted results.[3][1]
  3. Funding predicts which questions get asked. Comparisons between cheap old treatments rarely have a sponsor.[5][2]

Section 01

The split, condition by condition

Four of the five conditions follow the same shape: a company pays for most of the research, universities and hospitals fill in the rest, and government funding is a rounding error. Psoriasis and eczema attract the most money because both now have expensive injected medicines with long treatment courses behind them.[1][2]

Sponsor class across five skin conditions, 2026-08-20 registry snapshot
ConditionTotal trialsIndustry-funded
Psoriasis15761057[1]
Eczema1255869[1]
Acne629410[1]
Rosacea207123[1]
Melasma13131[3]

Section 02

Melasma, the condition nobody funds

Melasma inverts the pattern. Academic and hospital sponsors run 92 of its 131 trials; industry runs 31. The consequences show up immediately in the numbers that matter: 6.8 percent of completed melasma studies have posted results, against 43 percent for acne and 47 percent for psoriasis. Total enrolment across every melasma trial is 3,153 people. Psoriasis has 246,125.[3][1]

The reason is commercial rather than medical. Melasma is mostly treated with old, cheap, off-patent ingredients — hydroquinone, tretinoin, azelaic acid, tranexamic acid — and no company earns enough from those to fund a large trial. It also affects darker skin disproportionately, in populations that have historically been under-represented in dermatology research.[3][5]

So if melasma advice online feels vaguer and more contradictory than acne advice, that is not your imagination. The underlying evidence really is thinner, and it is thinner for reasons that have nothing to do with how much the condition affects people.[3][1]

Section 03

What sponsorship does and does not do

Industry trials tend to be larger, better controlled and more likely to post results, partly because law requires it for many registered studies. On the raw quality of the method, company money often buys a better study than a small academic grant can.[4][5]

The influence shows in framing rather than fraud. A sponsor chooses the comparison, the dose, the length and the outcome measured. A new medicine tested against a placebo for 12 weeks will look impressive without ever answering whether it beats a cheap generic over a year. Reviews of sponsorship consistently find that funded studies more often reach conclusions favourable to the funder.[5][2]

The most useful question is not whether a company paid, but what the study was allowed to compare itself against.[5]

Section 04

The questions with no sponsor

  • Head-to-head comparisons of two cheap generics. Neither maker gains from the answer, so almost nobody runs one.[5][2]
  • How long a treatment keeps working. Trials commonly run 12 to 16 weeks; conditions like acne and eczema last years.[1][2]
  • Whether combining two existing treatments beats either one. Combination evidence exists mainly where a company sells the combination.[2][5]
  • Whether results hold across skin tones. Enrolment often skews, and melasma shows what happens when the affected group has little commercial pull.[3][5]

Section 05

How to use this when reading about a treatment

When a treatment has surprisingly little evidence, check whether anyone had a reason to study it. Old off-patent ingredients and cosmetic actives are systematically under-researched relative to how much they are used, and that is a funding artefact rather than a verdict.[1][5]

When a treatment has impressive evidence, check the comparator. Beating a placebo is a low bar; beating the standard cheap option is the result that should change what you buy. Our per-condition pages list which comparisons were actually run.[1][2]

Your next step

Turn this into a practical plan

Choose the guide that best matches what you see. Each one starts with what to try, how long to wait and when to get help.

Keep reading

Related questions